Protagonist Therapeutics PTGX
$121.40 −$2.62 (-2.11%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $121.40 0.00%
Open$123.41
Prev close$124.02
Day range$120.15 – $125.91
Volume600.7K
Market cap$7.92B
P/E (TTM)25.7
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$274.41M+5,723.6% YoY
Operating profit$218.33M+570.3% YoY
Net profit$220.02M+659.3% YoY
Diluted EPS$3.07+595.2% YoY
Free cash flow-$23.46M-1,058.4% YoY
Operating cash flow-$23.22M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin99.6%
Operating margin58.6%
Net margin62.0%
Return on equity39.6%
Return on assets37.0%
Return on invested capital36.1%
Current ratio19.85
Liabilities / assets5.4%
Cash & investments$800.06M
Total debt$6.18M
Net cash (debt)$793.89M
Free cash flow / sales19.8%
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $274.41M | $213.48M | $56.37M | $46.02M | $7.44M |
| Total Operating Revenue | $274.41M | $213.48M | $56.37M | $46.02M | $7.44M |
| Cost of Revenue | $1.10M | – | – | – | – |
| Gross Profit | $273.31M | – | – | – | – |
| Operating Expense | $54.98M | $54.71M | $60.02M | $204.14M | $57.79M |
| Selling and Admin Expenses | $13.70M | $12.65M | $13.28M | $44.85M | $11.43M |
| -General & Admin Expense | $13.70M | $12.65M | $13.28M | $44.85M | $11.43M |
| Research & Development | $41.27M | $42.06M | $46.74M | $159.29M | $46.36M |
| Operating Profit | $218.33M | $158.77M | -$3.65M | -$158.13M | -$50.36M |
| Net Non-Operating Interest Income (Expense) | $8.25M | $6.43M | $5.88M | $28.79M | $6.76M |
| Non-Operating Interest Income | $8.25M | $6.43M | $5.88M | $28.79M | $6.76M |
| Other Income (Expense) | -$14,000.00 | -$81,000.00 | $53,000.00 | $27,000.00 | -$124,000.00 |
| Other Non-Operating Income (Expenses) | -$14,000.00 | -$81,000.00 | $53,000.00 | $27,000.00 | -$124,000.00 |
| Pretax Profit | $226.57M | $165.11M | $2.28M | -$129.31M | -$43.72M |
| Tax | $6.56M | $2.27M | -$1.50M | $838,000.00 | $666,000.00 |
| Net Profit | $220.02M | $162.85M | $3.78M | -$130.15M | -$44.38M |
| Profit from Continuing Operations | $220.02M | $162.85M | $3.78M | -$130.15M | -$44.38M |
| Net Income to Parent Company | $220.02M | $162.85M | $3.78M | -$130.15M | -$44.38M |
| Net Income to Common Stockholders | $220.02M | $162.85M | $3.78M | -$130.15M | -$44.38M |
| Basic EPS | $3.32 | $2.47 | $0.06 | -$2.05 | -$0.69 |
| Diluted EPS | $3.07 | $2.29 | $0.05 | -$2.05 | -$0.69 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $1.15B | $885.54M | $697.46M | $668.19M | $668.19M |
| Total Current Assets | $1.10B | $807.15M | $613.46M | $577.57M | $577.57M |
| Cash and Cash Equivalents & Short-Term Investments | $800.06M | $782.58M | $547.79M | $567.36M | $567.36M |
| -Cash and Cash Equivalents | $498.30M | $420.08M | $193.71M | $128.39M | $128.39M |
| -Short Term Investments | $301.77M | $362.50M | $354.07M | $438.97M | $438.97M |
| Receivables | $290.91M | $19.64M | $57.12M | $4.50M | $4.50M |
| -Accrued Interest Receivable | $3.12M | $2.86M | $3.46M | $4.37M | $4.37M |
| -Due from Related Parties Current | $283.79M | $13.42M | $53.66M | $121,000.00 | $121,000.00 |
| -Other Receivables | $4.01M | $3.37M | – | $10,000.00 | $10,000.00 |
| Prepaid Assets | $3.96M | $2.62M | $3.99M | $5.71M | $5.71M |
| Other Current Assets | $6.12M | $2.31M | $4.56M | – | – |
| Total Non-Current Assets | $45.49M | $78.40M | $84.00M | $90.61M | $90.61M |
| Net PPE | $9.82M | $10.40M | $11.17M | $11.69M | $11.69M |
| -Gross PPE | $19.34M | $19.52M | $19.89M | $20.00M | $20.00M |
| -Accumulated Depreciation | -$9.53M | -$9.12M | -$8.72M | -$8.32M | -$8.32M |
| Investments and Advances | $34.56M | $66.88M | $72.55M | $78.64M | $78.64M |
| -Available for Sale Securities | $34.56M | – | – | – | – |
| Other Non-Current Assets | $1.12M | $1.12M | $288,000.00 | $287,000.00 | $287,000.00 |
| Total Liabilities | $61.64M | $44.00M | $41.99M | $53.48M | $53.48M |
| Total Current Liabilities | $55.46M | $37.18M | $34.55M | $45.44M | $45.44M |
| Payables | $10.72M | $3.63M | $8.94M | $5.52M | $5.52M |
| -Accounts Payable | $5.92M | $3.46M | $8.44M | $5.34M | $5.34M |
| -Total Tax Payable | $4.22M | – | – | $0.00 | $0.00 |
| -Other Payable | $577,000.00 | $175,000.00 | $502,000.00 | $185,000.00 | $185,000.00 |
| Current Accrued Expenses | $14.73M | $15.85M | $12.76M | $15.32M | $15.32M |
| Short-Term Debt and Capital Lease Obligation | $2.45M | $2.40M | $2.34M | $2.28M | $2.28M |
| -Current Capital Lease Obligation | $2.45M | $2.40M | $2.34M | $2.28M | $2.28M |
| Current Deferred Liabilities | $16.31M | $9.66M | $6.28M | $9.55M | $9.55M |
| Total Non-Current Liabilities | $6.18M | $6.82M | $7.44M | $8.04M | $8.04M |
| Long Term Debt and Capital Lease Obligation | $6.18M | $6.82M | $7.44M | $8.04M | $8.04M |
| -Long Term Capital Lease Obligation | $6.18M | $6.82M | $7.44M | $8.04M | $8.04M |
| Total Equity | $1.08B | $841.54M | $655.47M | $614.71M | $614.71M |
| Stockholders' Equity | $1.08B | $841.54M | $655.47M | $614.71M | $614.71M |
| Capital Stock | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 |
| -Common Stock | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $1.18B | $1.15B | $1.12B | $1.08B | $1.08B |
| Retained Earnings | -$84.02M | -$304.04M | -$466.89M | -$470.67M | -$470.67M |
| Less: Treasury Stock | -$5.79M | – | – | – | – |
| Gains/Losses Not Affecting Retained Earnings | -$1.30M | -$828,000.00 | -$269,000.00 | $641,000.00 | $641,000.00 |
| Non-Current Deferred Liabilities | – | – | – | $0.00 | $0.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$23.22M | $219.05M | -$48.94M | $57.67M | -$36.98M |
| Net cash flow from continuing operations | -$23.22M | $219.05M | -$48.94M | $57.67M | -$36.98M |
| Net Income from Continuing Operations | $220.02M | $162.85M | $3.78M | -$130.15M | -$44.38M |
| Depreciation & Depletion & Amortization | $409,000.00 | $397,000.00 | $407,000.00 | $1.28M | $376,000.00 |
| Other Non-Cash Items | $450,000.00 | $440,000.00 | $439,000.00 | $1.58M | $333,000.00 |
| Change in Working Capital | -$257.37M | $42.37M | -$67.06M | $146.21M | -$2.67M |
| -Change in Receivables | -$271.01M | $36.88M | -$53.54M | $164.88M | $462,000.00 |
| -Change in Prepaid Assets | -$403,000.00 | $4.22M | -$1.92M | -$2.36M | -$365,000.00 |
| -Change in Payables and Accrued Expense | $7.98M | -$710,000.00 | -$7.79M | $5.61M | $5.10M |
| -Change in Other Current Assets | $0.00 | – | – | – | – |
| -Change in Other Current Liabilities | -$585,000.00 | -$560,000.00 | -$547,000.00 | -$903,000.00 | -$426,000.00 |
| -Change In Other Working Capital | $6.65M | $3.38M | -$3.27M | -$21.02M | -$7.44M |
| Net cash flow from investing | $93.43M | -$2.43M | $90.89M | -$49.33M | $48.82M |
| Net Cash Flow from Continuing Investing Activities | $93.43M | -$2.43M | $90.89M | -$49.33M | $48.82M |
| Net PPE Purchase and Sale | -$237,000.00 | -$168,000.00 | -$215,000.00 | -$1.59M | -$144,000.00 |
| Net Investment Purchase and Sale | $93.67M | -$2.26M | $91.11M | -$47.74M | $48.96M |
| Financing Cash Flow | $8.01M | $9.74M | $23.37M | $22.86M | $2.84M |
| Net Cash Flow from Continuing Financing Activities | $8.01M | $9.74M | $23.37M | $22.86M | $2.84M |
| Proceeds from Stock Option Exercised | $13.80M | $9.74M | $23.37M | $23.34M | $2.84M |
| Ending Cash Balance | $498.59M | $420.37M | $194.00M | $128.68M | $128.68M |
| Net Change in Cash | $78.22M | $226.37M | $65.32M | $31.20M | $14.68M |
| Beginning Cash Balance | $420.37M | $194.00M | $128.68M | $97.47M | $114.00M |
| Free Cash Flow | -$23.46M | $218.88M | -$49.16M | $56.08M | -$37.12M |
| Gain/Loss from Continuing Operations | – | – | -$2,000.00 | – | – |
| Net Common Stock Issuance | – | – | – | $0.00 | $0.00 |
| Net Other Financing Charges | – | – | – | -$479,000.00 | $0.00 |
No comments yet — be the first to weigh in on PTGX.
Sign in to join the discussion.